Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm

Table 1 Mammalian target of rapamycin inhibitors for patients engrafted for hepatocellular carcinoma

	No. (SRL/non-SRL)	5-year OS (%)	5-year DFS (%)	HAT (%)	ACR (%)	Discontinuation for toxicity (%)
Prospective controlled trial
Geissler et al[21], 2016	261/264	79.4/70.33	72.6/68.4	-	23.4/17.0	-
Meta-analysis
Liang et al[22], 2012	332/2615	OR: 2.473	1 yr: OR 2.413	OR: 1.32	-	-
Zhang et al[23], 2018	7695	OR: 1.683	1 yr: OR 2.133	-	-	-
Case-control
Vivarelli et al[24],2010	31/31	-	3 yr 86/563	0/0	3.2/3.2	-
Retrospective cohort
Zimmerman et al[25],2007	45/52	80/62	78.8/54	2.4/1.9	20/19.6	-
Zhou et al[28], 20081	27/46	19.8 ± 1.2/16.0 ± 1.423	17.3 ± 1.4/15.9 ± 1.62	0/0	30.4/19.6	8.3
Chinnakotla et al[26], 2009	121/106	80/503	-	1.9/2	62.8/54.7	0
Toso et al[27], 2010	109/2382	83.1/68.73	-	-	-	-

¹All tumours were beyond Milan criteria;

²Median survival in months;

³Statistically significant. SRL: Sirolimus; OS: Overall survival; DFS: Disease-free survival; HAT: Hepatic artery thrombosis; ACR: Acute cellular rejection.